Dr. Panageas is involved in the analysis of cluster correlated data and random effects models in the context of health services research. She is currently involved in developing a framework for hospital profiling in cancer care in collaboration with the Health Outcomes Group and members of the Health Policy Center. Profiling hospitals and/or physicians based on the quality of care they provide to patients is a priority for policy makers, payers, and the public. Dr. Panageas’ future research interests lie in evaluating current methodology to profile providers in order to identify those providers that provide significantly better or significantly worse quality of care than the majority, given the case-mix of their patients. Dr. Panageas primarily collaborates with the Melanoma and Immunotherapeutics Service and the Department of Neurology (member of the Brain Tumor Center) to design and analyze prospective and retrospective studies to evaluate treatment strategies including immuno-therapies, explore various biomarkers, develop prediction models and develop models to estimate the risk of developing distant metastasis or local recurrence. She is particularly interested in linking peripheral blood T cell phenotype with genomic features and clinical outcome in patients treated with checkpoint inhibition. She serves on the editorial board of the Journal of the National Cancer Institute, JNCI Cancer Spectrum, Clinical Cancer Research, and Scientific Reports Nature and continues to serve on the faculty at the ASCO/AACR Vail Clinical Methods Workshop.